Lifesci Capital Upgrades vTv Therapeutics (NASDAQ:VTVT) to Strong-Buy

Key Points

• Lifesci Capital upgraded vTv Therapeutics to “strong buy,” while analysts overall maintain a “Moderate Buy” consensus with an average price target of $55.83.
• vTv Therapeutics shares opened at $33.47, with a market capitalization of approximately $131.87 million and a 52-week trading range of $18.00 to $44.00.
• The company reported quarterly EPS of -$1.05, missing the consensus estimate of -$0.97; analysts expect a full-year loss of approximately $2.35 per share.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was upgraded by stock analysts at Lifesci Capital to a "strong-buy" rating in a note issued to investors on Wednesday, Zacks reports.

Several other research analysts also recently commented on the company. Weiss Ratings downgraded vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. BTIG Research boosted their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. HC Wainwright lowered their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Zacks Research downgraded vTv Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Friday, August 7th. Finally, Rodman & Renshaw initiated coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They set a "buy" rating and a $67.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, vTv Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $55.83.

vTv Therapeutics Stock Performance

vTv Therapeutics stock opened at $33.47 on Wednesday. The stock has a market cap of $131.87 million, a PE ratio of -31.58 and a beta of 0.29. The firm's 50-day simple moving average is $33.05 and its 200 day simple moving average is $34.57. vTv Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). As a group, analysts predict that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the fourth quarter worth $731,000. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics in the 4th quarter worth approximately $221,000. Finally, Geode Capital Management LLC boosted its holdings in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock valued at $1,128,000 after acquiring an additional 12,896 shares in the last quarter. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source